Parameter | Concurrent Untreated Control Group | L-374,087 10 mg/kg p.o. every 12 h |
---|---|---|
Jugular vein thrombosis | ||
Jugular vein 24-h thrombus mass (mg) | 34.9 ± 6.8 (n = 14) | 13.8 ± 3.1 (n= 7)* |
Left circumflex coronary artery thrombosis | ||
Incidence of myocardial ischemia | 9/9 | 3/5 |
Time to myocardial ischemia (min)3-a | 108.1 ± 23.9 (n = 9) | 385.7 ± 14.4 (n = 3)** |
Incidence of arrhythmic mortality | 3/9 | 1/5 |
24-h left circumflex coronary artery thrombus mass (mg) | 10.8 ± 2.0 (n = 6) | 1.0 ± 0.7 (n = 4)** |
24-h myocardial infarct size (% LV) | 29.2 ± 5.0 (n = 6) | 5.0 ± 2.9 (n = 4)** |
Data are mean ± S.E.M., *p < .05, **p < .01 compared with concurrent untreated control group value. First oral dose of L-374,087 was administered 1 h before initiation of electrolytic injury to jugular vein and left circumflex coronary artery; the second oral dose of L-374,087 was administered 12 h after the first dose.
↵3-a Time after the initiation of left circumflex coronary artery electrical stimulation.